1. A pharmaceutical composition comprising an activated-potentiated form of antibodies to the insulin receptor and an activated-potentiated form of antibodies to endothelial NO-sintaze.2. A pharmaceutical composition according to claim 1, characterized in that it comprises an activated-potentiated form of antibodies to the β-subunit of the insulin receptor and an activated-potentiated form of antibodies to endothelial NO-sintaze.3. A pharmaceutical composition according to claim 1 or 2, characterized in that it comprises an activated-potentiated form of antibodies to the C-terminal fragment of β-subunit of the insulin receptor and an activated-potentiated form of antibodies to endothelial NO-sintaze.4. A pharmaceutical composition according to claim 3, characterized in that the activated-potentiated form of antibodies to the C-terminal fragment of β-subunit of the insulin receptor and an activated-potentiated form of antibodies to endothelial NO-synthase is used in the activated-potentiated form aqueous or aqueous-alcoholic solution, activity is due to process multiple dilutions respective matrix solution of antibodies in an aqueous or aqueous-alcoholic solvent in combination with an external mechanical impact - mnogokr atnym shaking each razvedeniya.5. A pharmaceutical composition according to claim 3, characterized in that formed in the solid dosage form contains an effective amount of granules of the neutral carrier saturated with a mixture of the activated-potentiated form of antibodies to the C-terminal fragment of β-subunit of the insulin receptor and an activated-potentiated form of antibodies to endothelial NO synthase, and a Pharmaceutical1. Фармацевтическая композиция, содержащая активированную-потенцированную форму антител к рецептору инсулина и активированную-потенцированную форму антител к эндотелиальной NO-синтазе.2. Фармацевтическая композиция по п.1, отличающаяся тем, что содержит активированную-потенцированную форму антител к β-субъединице рецептора
